Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199717 | 1.00 | SLC6A9 (0.53) | SLC6A9CCR5SLC18A3DRD2SIGMAR1 | |
| SCHEMBL8199718 | 1.00 | SLC6A9 (0.53) | SLC6A9CCR5SLC18A3DRD2SIGMAR1 | |
| SCHEMBL8236868 | 0.90 | SLC6A9 (0.51) | SLC6A9DRD2GRIN1GRIN2B | |
| SCHEMBL5904205 | 0.85 | SLC6A9 (0.46) | SLC6A9SIGMAR1 | |
| SCHEMBL11525123 | 0.82 | MAPT (0.46) | SLC6A9 | |
| SCHEMBL6500564 | 0.82 | CD274 (0.47) | CCR5SLC18A3GRIN1GRIN2B | |
| SCHEMBL8203174 | 0.79 | HRH3 (0.45) | SLC18A3DRD2SIGMAR1GRIN1GRIN2B | |
| SCHEMBL8203170 | 0.79 | HRH3 (0.45) | SLC18A3DRD2SIGMAR1GRIN1GRIN2B | |
| SCHEMBL8203171 | 0.79 | HRH3 (0.45) | SLC18A3DRD2SIGMAR1GRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL9520222 | 0.78 | ADRA2A (0.46) | DRD2SIGMAR1HTR1ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| US-6048877-A | Tetralone derivatives as antiarrhythmic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | SLC6A9 1210/4885CCR5 206/4885SLC18A3 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.